Home › Compound Library › Galcanezumab (Emgality)

Galcanezumab (Emgality)

Biologicprescriptionsubcutaneous · inferred

Humanized IgG4 monoclonal antibody binding the CGRP ligand; approved for migraine prevention and episodic cluster headache. 240 mg SC loading dose then 120 mg monthly for migraine; 300 mg SC monthly during cluster periods. Terminal half-life ~27 days.

Projected serum levels — 120 mg, custom (shown daily)

Galcanezumab (Emgality)
Galcanezumab (Emgality) modeled serum levels, 120 mg custom (shown daily) over 121 days Population-based pharmacokinetic estimate. Steady state reached after approximately 78 days. 0 1.3k 2.5k 3.8k 5k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule ≈ steady state · day 78
Galcanezumab (Emgality) modeled serum levels with a loading dose of 360 mg, then 120 mg custom (shown daily) The first dose is larger so levels approach steady state faster. 0 1.3k 2.5k 3.8k 5k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule

Maintenance schedule: 120 mg custom (shown daily) (subcutaneous).

Loading schedule: 360 mg on day 1, then 120 mg custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~78 days: peak ≈ 4.5k mg, trough ≈ 4.5k mg body load. Population-based estimate over 121 days for a 120 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Biologic
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
27 days
Common dose
120 mg
Suggested maximum
300 mg/day
Reference dose range
60–300 mg (single dose)
Suggested cadence
custom (shown daily)
Validated against
240 mg sc — Cmax 30 mg/L at 120 h

Documented interactions

  • watch
    Fremanezumab (Ajovy) + Galcanezumab (Emgality) Stacked effects

    Fremanezumab (Ajovy) and Galcanezumab (Emgality) both push the cgrp ligand in the same direction.

Serum checks 1 modeled interaction pairings for galcanezumab (emgality) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. A single-dose, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety, and immunogenicity of galcanezumab in healthy Japanese and Caucasian subjects Kielbasa W et al. · Cephalalgia, 2019 DOI

    First-in-human PK bridging study establishing galcanezumab's ~27-day terminal half-life and dose-proportional exposure across populations.

  2. Evaluation of galcanezumab for the prevention of episodic migraine (EVOLVE-1) Stauffer VL et al. · JAMA Neurology, 2018 DOI

    EVOLVE-1 phase 3 trial demonstrating galcanezumab 120 mg and 240 mg monthly significantly reduced migraine days in episodic migraine.

2 published studies referenced in the app, each with a plain-language summary.